Founded by John and Ian, brought together through their mutual love of chasing challenges, Phycobloom is a cutting-edge clean technology start-up, aiming to revolutionise biofuel production by harnessing the power of algae.
Natasha Barrow
December 13, 2024
We all produce data every day, either through downloading music, snapping photos, or writing documents, but rarely do we stop and think about where this information is physically stored. The digital universe encompasses all the world’s digital data, and much like the physical universe it is expanding at an exponential rate. Does biology hold the solution to data storage?
Aonghus Topham
December 13, 2024
After coming across phytosterols and phytostanols during my degree, I was intrigued by the growing evidence indicating therapeutic potential as anticancer agents. However, these compounds are not new and have been long known to help reduce cholesterol. This blog post will summarise the benefits of phytosterols and phytostanols and describe how they are marketed as functional food products. The aim of these products is to reduce cholesterol levels which are a risk factor for heart disease and are designed for those who need help with cholesterol level management.
Lewis Wallis
December 13, 2024
On November 3rd 2021, the Chinese National Healthcare and Security Administration (NHSA) announced updates on the National Reimbursement Drug List (NRDL). Out of the 85 new drugs being negotiated, 67 made it to the NRDL, with an average price drop of 61.7%. Of note was one drug, Spinraza (molecule name Nusinersen), which saw a 95% price slash from CNY 700,000 (US$108,500) to CNY 33,000 (US$5,180) per dose. Treating spinal muscular atrophy (SMA), Spinraza will be the first reimbursed medicine for this rare disease that affects only one in every 8 thousand new-borns in China.
Hanzhong Bai
December 13, 2024
In Part 1 of the story we discussed the birth of Spinraza and its market access inChina. Here in Part 2, we will continue the story on the competitive landscape ofSMA drugs and Biogen’s revenue challenges in 2021.
Hanzhong Bai
December 13, 2024
Sign up for our monthly newsletter of upcoming events, recently published insights and SEC updates.
